“Are there differences in the treatment strategies and outcomes between high-risk multiple myeloma patients and those with low-risk disease and without comorbities?”, Hematol Meeting Rep, vol. 2, no. 7, Jun. 2009, doi: 10.4081/hmr.v2i7.407.